Philip J Rosenthal

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6201688/philip-j-rosenthal-publications-by-year.pdf
Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

253 papers	11,895 citations	63 h-index	100 g-index
275 ext. papers	13,599 ext. citations	7.6 avg, IF	6.58 L-index

#	Paper	IF	Citations
253	Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries.. *JAMA Pediatrics*, **2022**,	8.3	5
252	Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria.. *Journal of Medicinal Chemistry*, **2022**,	8.3	2
251	Impact of Short-Term Storage on Antimalarial Susceptibilities of Fresh Ugandan Plasmodium falciparum Isolates.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0143721	5.9	
250	Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity.. *European Journal of Medicinal Chemistry*, **2022**, 236, 114324	6.8	0
249	Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183.. *Nature Communications*, **2022**, 13, 2158	17.4	0
248	Functionalized 3-hydroxy-3-aminoquinoline-oxindole hybrids as promising dual-function anti-plasmodials. *European Journal of Medicinal Chemistry Reports*, **2022**, 5, 100052		1
247	Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children. *Nature Communications*, **2021**, 12, 6714	17.4	1
246	Comparative Analysis of Genotyping via SNP Detection, Microsatellite Profiling, and Whole-Genome Sequencing. *Antimicrobial Agents and Chemotherapy*, **2021**, AAC0116321	5.9	1
245	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice. *Angewandte Chemie - International Edition*, **2021**, 60, 9279-9283	16.4	5
244	Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series. *Journal of Medicinal Chemistry*, **2021**, 64, 6085-6136	8.3	3
243	Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183 **2021**,		1
242	Balanced impacts of fitness and drug pressure on the evolution of PfMDR1 polymorphisms in Plasmodium falciparum. *Malaria Journal*, **2021**, 20, 292	3.6	1
241	A trio of quinoline-isoniazid-phthalimide with promising antiplasmodial potential: Synthesis, in-vitro evaluation and heme-polymerization inhibition studies. *Bioorganic and Medicinal Chemistry*, **2021**, 39, 116159	3.4	3
240	Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study. *Lancet Infectious Diseases, The*, **2021**, 21, 1568-1578	25.5	11
239	K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. *ELife*, **2021**, 10,	8.9	21
238	Changing Prevalence of Potential Mediators of Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda. *Journal of Infectious Diseases*, **2021**, 223, 985-994	7	35
237	Within-household clustering of genetically related Plasmodium falciparum infections in a moderate transmission area of Uganda. *Malaria Journal*, **2021**, 20, 68	3.6	0

236	Diversity of KIR genes and their HLA-C ligands in Ugandan populations with historically varied malaria transmission intensity. *Malaria Journal*, **2021**, 20, 111	3.6	1
235	The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to parasite resistance. *Science Translational Medicine*, **2021**, 13,	17.5	3
234	Has artemisinin resistance emerged in Africa?. *Lancet Infectious Diseases, The*, **2021**, 21, 1056-1057	25.5	9
233	Drug susceptibility of in eastern Uganda: a longitudinal phenotypic and genotypic study. *Lancet Microbe, The*, **2021**, 2, e441-e449	22.2	5
232	Associations between Varied Susceptibilities to PfATP4 Inhibitors and Genotypes in Ugandan Plasmodium falciparum Isolates. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0077121	5.9	
231	Deletions of pfhrp2 and pfhrp3 genes were uncommon in rapid diagnostic test-negative Plasmodium falciparum isolates from Uganda. *Malaria Journal*, **2021**, 20, 4	3.6	0
230	Design, synthesis, crystal structure and anti-plasmodial evaluation of tetrahydrobenzo[4,5]thieno[2,3-]pyrimidine derivatives. *RSC Medicinal Chemistry*, **2021**, 12, 970-981	3.5	4
229	Artemisinin resistance in Africa: How urgent is the threat?. *Med*, **2021**, 2, 1287-1288	31.7	3
228	Piperaquine induced QTc prolongation decreases with repeated monthly dihydroartemisinin-piperaquine dosing in pregnant Ugandan women. *Clinical Infectious Diseases*, **2021**,	11.6	1
227	The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC. *Nature Communications*, **2020**, 11, 2107	17.4	25
226	Antimalarial Trioxolanes with Superior Drug-Like Properties and In Vivo Efficacy. *ACS Infectious Diseases*, **2020**, 6, 1827-1835	5.5	10
225	Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials. *Journal of Medicinal Chemistry*, **2020**, 63, 6179-6202	8.3	5
224	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations. *PLoS ONE*, **2020**, 15, e0233893	3.7	3
223	Amalgamating Isatin/Indole/Nitroimidazole with 7-chloroquinolines via azide-alkyne cycloaddition: Synthesis, anti-plasmodial, and cytotoxic evaluation. *Chemical Biology and Drug Design*, **2020**, 96, 1355-1361	2.9	4
222	Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation. *MBio*, **2020**, 11,	7.8	11
221	Are three drugs for malaria better than two?. *Lancet, The*, **2020**, 395, 1316-1317	40	8
220	Associations between red blood cell variants and malaria among children and adults from three areas of Uganda: a prospective cohort study. *Malaria Journal*, **2020**, 19, 21	3.6	7
219	The Impact of Control Interventions on Malaria Burden in Young Children in a Historically High-Transmission District of Uganda: A Pooled Analysis of Cohort Studies from 2007 to 2018. *American Journal of Tropical Medicine and Hygiene*, **2020**, 103, 785-792	3.2	6

218	Malaria Diagnosed in an Urban Setting Strongly Associated with Recent Overnight Travel: A Case-Control Study from Kampala, Uganda. *American Journal of Tropical Medicine and Hygiene*, **2020**, 103, 1517-1524	3.2	1
217	The Importance of Diagnostic Testing during a Viral Pandemic: Early Lessons from Novel Coronavirus Disease (COVID-19). *American Journal of Tropical Medicine and Hygiene*, **2020**, 102, 915-916	3.2	17
216	Perspectives on Battling COVID-19 in Countries of Latin America and the Caribbean. *American Journal of Tropical Medicine and Hygiene*, **2020**, 103, 593-596	3.2	21
215	Keep Politics out of Funding Decisions for Medical Research and Public Health. *American Journal of Tropical Medicine and Hygiene*, **2020**, 103, 931-932	3.2	2
214	Falcipain cysteine proteases of malaria parasites: An update. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2020**, 1868, 140362	4	12
213	Functionalized Naphthalimide-4-aminoquinoline Conjugates as Promising Antiplasmodials, with Mechanistic Insights. *ACS Medicinal Chemistry Letters*, **2020**, 11, 154-161	4.3	8
212	Synthesis, anti-plasmodial and cytotoxic evaluation of 1H-1,2,3-triazole/acyl hydrazide integrated tetrahydro-β-carboline-4-aminoquinoline conjugates. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 126810	2.9	17
211	Design, synthesis, heme binding and density functional theory studies of isoindoline-dione-4-aminoquinolines as potential antiplasmodials. *Future Medicinal Chemistry*, **2020**, 12, 193-205	4.1	6
210	Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	2
209	Resistance to Some But Not Other Dimeric Lindenane Sesquiterpenoid Esters Is Mediated by Mutations in a Esterase. *ACS Infectious Diseases*, **2020**, 6, 2994-3003	5.5	1
208	Associations between Malaria-Preventive Regimens and Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Ugandan Pregnant Women. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	4
207	Associations between Aminoquinoline Resistance Genotypes and Clinical Presentations of Plasmodium falciparum Infection in Uganda. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	3
206	Association between recent overnight travel and use of long-lasting insecticidal nets in rural Uganda: a prospective cohort study in Tororo. *Malaria Journal*, **2020**, 19, 405	3.6	4
205	Impact of a Rapid Decline in Malaria Transmission on Antimalarial IgG Subclasses and Avidity. *Frontiers in Immunology*, **2020**, 11, 576663	8.4	3
204	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations **2020**, 15, e0233893		
203	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations **2020**, 15, e0233893		
202	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations **2020**, 15, e0233893		
201	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations **2020**, 15, e0233893		

200	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations **2020**, 15, e0233893		
199	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations **2020**, 15, e0233893		
198	Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. *Nature Communications*, **2019**, 10, 480	17.4	13
197	Metagenomic next-generation sequencing of samples from pediatric febrile illness in Tororo, Uganda. *PLoS ONE*, **2019**, 14, e0218318	3.7	33
196	Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 1310-1318	6.1	3
195	Understanding the context of delays in seeking appropriate care for children with symptoms of severe malaria in Uganda. *PLoS ONE*, **2019**, 14, e0217262	3.7	10
194	Improvement of Asparagine Ethylenediamines as Anti-malarial -Selective Proteasome Inhibitors. *Journal of Medicinal Chemistry*, **2019**, 62, 6137-6145	8.3	19
193	Falcipain Inhibitors Based on the Natural Product Gallinamide A Are Potent in Vitro and in Vivo Antimalarials. *Journal of Medicinal Chemistry*, **2019**, 62, 5562-5578	8.3	13
192	Malaria: How Are We Doing and How Can We Do Better?. *American Journal of Tropical Medicine and Hygiene*, **2019**, 100, 239-241	3.2	7
191	Substituted 1,3-dioxoisoindoline-4-aminoquinolines coupled via amide linkers: Synthesis, antiplasmodial and cytotoxic evaluation. *Bioorganic Chemistry*, **2019**, 88, 102912	5.1	9
190	Association Between Recent Overnight Travel and Risk of Malaria: A Prospective Cohort Study at 3 Sites in Uganda. *Clinical Infectious Diseases*, **2019**, 68, 313-320	11.6	9
189	A shorter course for anti-relapse therapy against vivax malaria. *Lancet, The*, **2019**, 394, 898-900	40	1
188	Antimalarial drug resistance in Africa: the calm before the storm?. *Lancet Infectious Diseases, The*, **2019**, 19, e338-e351	25.5	111
187	Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: A cluster-randomized, placebo-controlled trial. *PLoS Medicine*, **2019**, 16, e1002835	11.6	24
186	Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. *Nature Communications*, **2019**, 10, 2816	17.4	24
185	[(7-chloroquinolin-4-yl)amino]acetophenones and their copper(II) derivatives: Synthesis, characterization, computational studies and antimalarial activity. *EXCLI Journal*, **2019**, 18, 962-987	2.4	
184	Distinct Biomarker Profiles Distinguish Malawian Children with Malarial and Non-malarial Sepsis. *American Journal of Tropical Medicine and Hygiene*, **2019**, 101, 1424-1433	3.2	3
183	Be Careful What You Eat!. *American Journal of Tropical Medicine and Hygiene*, **2019**, 101, 955-956	3.2	1

182	The Diversity of the K13 Propeller Domain Did Not Increase after Implementation of Artemisinin-Based Combination Therapy in Uganda. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	6
181	Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: a sub-study of a cluster randomized trial. *Malaria Journal*, **2019**, 18, 389	3.6	4
180	Coupling the Antimalarial Cell Penetrating Peptide TP10 to Classical Antimalarial Drugs Primaquine and Chloroquine Produces Strongly Hemolytic Conjugates. *Molecules*, **2019**, 24,	4.8	8
179	Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	24
178	Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	9
177	Persistent Parasitemia Despite Dramatic Reduction in Malaria Incidence After 3 Rounds of Indoor Residual Spraying in Tororo, Uganda. *Journal of Infectious Diseases*, **2019**, 219, 1104-1111	7	18
176	Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children. *Journal of Infectious Diseases*, **2019**, 219, 1112-1120	7	25
175	Plasmodium falciparum Falcipain-2a Polymorphisms in Southeast Asia and Their Association With Artemisinin Resistance. *Journal of Infectious Diseases*, **2018**, 218, 434-442	7	18
174	Endoperoxide-8-aminoquinoline hybrids as dual-stage antimalarial agents with enhanced metabolic stability. *European Journal of Medicinal Chemistry*, **2018**, 149, 69-78	6.8	20
173	Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. *Journal of Infectious Diseases*, **2018**, 217, 964-972	7	10
172	Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. *Clinical Infectious Diseases*, **2018**, 67, 1079-1088	11.6	12
171	Clinical consequences of submicroscopic malaria parasitaemia in Uganda. *Malaria Journal*, **2018**, 17, 67	3.6	13
170	Cysteine proteases in protozoan parasites. *PLoS Neglected Tropical Diseases*, **2018**, 12, e0006512	4.8	59
169	Microwave-promoted facile access to 4-aminoquinoline-phthalimides: Synthesis and anti-plasmodial evaluation. *European Journal of Medicinal Chemistry*, **2018**, 143, 150-156	6.8	18
168	Caregiver responses and association with delayed care-seeking in children with uncomplicated and severe malaria. *Malaria Journal*, **2018**, 17, 476	3.6	7
167	Molecular assays for antimalarial drug resistance surveillance: A target product profile. *PLoS ONE*, **2018**, 13, e0204347	3.7	15
166	Associations between erythrocyte polymorphisms and risks of uncomplicated and severe malaria in Ugandan children: A case control study. *PLoS ONE*, **2018**, 13, e0203229	3.7	9
165	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E6863-E6870	11.5	37

164	Targeting CPSF3 as a new approach to control toxoplasmosis. *EMBO Molecular Medicine*, **2017**, 9, 385-394	12	37
163	The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*, **2017**, 65, 486-494	11.6	19
162	Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate. *Journal of Medicinal Chemistry*, **2017**, 60, 5889-5908	8.3	40
161	Piperazine-linked 4-aminoquinoline-chalcone/ferrocenyl-chalcone conjugates: Synthesis and antiplasmodial evaluation. *Chemical Biology and Drug Design*, **2017**, 90, 590-595	2.9	12
160	Marked variation in prevalence of malaria-protective human genetic polymorphisms across Uganda. *Infection, Genetics and Evolution*, **2017**, 55, 281-287	4.5	6
159	Changing Antimalarial Drug Sensitivities in Uganda. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	39
158	Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. *Journal of Infectious Diseases*, **2017**, 216, 1008-1017	7	19
157	Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Drug Sensitivity-Associated Haplotypes in Uganda. *Open Forum Infectious Diseases*, **2017**, 4, ofw229	1	24
156	A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. *Nature Communications*, **2017**, 8, 14574	17.4	70
155	4-Aminoquinoline-chalcone/-N-acetylpyrazoline conjugates: Synthesis and antiplasmodial evaluation. *European Journal of Medicinal Chemistry*, **2017**, 138, 993-1001	6.8	38
154	Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs). *Journal of Medicinal Chemistry*, **2017**, 60, 6911-6923	8.3	31
153	Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda. *Malaria Journal*, **2017**, 16, 67	3.6	13
152	Drug resistance mediating Plasmodium falciparum polymorphisms and clinical presentations of parasitaemic children in Uganda. *Malaria Journal*, **2017**, 16, 125	3.6	5
151	Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	7
150	4-Aminoquinoline-ferrocenyl-chalcone conjugates: Synthesis and anti-plasmodial evaluation. *European Journal of Medicinal Chemistry*, **2017**, 125, 269-277	6.8	48
149	Demographic, Socioeconomic, and Geographic Factors Leading to Severe Malaria and Delayed Care Seeking in Ugandan Children: A Case-Control Study. *American Journal of Tropical Medicine and Hygiene*, **2017**, 97, 1513-1523	3.2	23
148	Mass Azithromycin and Malaria Parasitemia in Niger: Results from a Community-Randomized Trial. *American Journal of Tropical Medicine and Hygiene*, **2017**, 97, 696-701	3.2	9
147	Performance of Loop-Mediated Isothermal Amplification for the Identification of Submicroscopic Infection in Uganda. *American Journal of Tropical Medicine and Hygiene*, **2017**, 97, 1777-1781	3.2	11

146	Species Infecting Children Presenting with Malaria in Uganda. *American Journal of Tropical Medicine and Hygiene*, **2017**, 97, 753-757	3.2	24
145	Comparative Prevalence of Resistance-Associated Genetic Polymorphisms in Parasites Infecting Humans and Mosquitoes in Uganda. *American Journal of Tropical Medicine and Hygiene*, **2017**, 97, 1576-1580	3.2	5
144	"The Way We Were". *American Journal of Tropical Medicine and Hygiene*, **2017**, 97, 1955-1957	3.2	
143	Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda. *Journal of Infectious Diseases*, **2017**, 215, 631-635	7	33
142	Probing the Azaaurone Scaffold against the Hepatic and Erythrocytic Stages of Malaria Parasites. *ChemMedChem*, **2016**, 11, 2194-2204	3.7	14
141	Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5817-27	5.9	41
140	Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5649-54	5.9	21
139	Antimalarial Benzoxaboroles Target Plasmodium falciparum Leucyl-tRNA Synthetase. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4886-95	5.9	39
138	Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. *Journal of Infectious Diseases*, **2016**, 213, 1134-42	7	57
137	Novel squaramides with in vitro liver stage antiplasmodial activity. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 1786-92	3.4	14
136	Artefenomel: a promising new antimalarial drug. *Lancet Infectious Diseases, The*, **2016**, 16, 6-8	25.5	19
135	Communicable Diseases: A Global Perspective. *American Journal of Tropical Medicine and Hygiene*, **2016**, 95, 974-975	3.2	
134	Characterizing microscopic and submicroscopic malaria parasitaemia at three sites with varied transmission intensity in Uganda. *Malaria Journal*, **2016**, 15, 470	3.6	35
133	Measures of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor Residual Spraying at Three Sites in Uganda: A Prospective Observational Study. *PLoS Medicine*, **2016**, 13, e1002167	11.6	86
132	The proteolytic repertoire of malaria parasites **2016**, 325-352		0
131	Long-chain alkyl-substituted gentisic acid and benzoquinone derivatives from the root of Micronychia tsiramiramy (Anacardiaceae). *Zeitschrift Fur Naturforschung - Section B Journal of Chemical Sciences*, **2016**, 71, 297-303	1	0
130	Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. *Journal of Infectious Diseases*, **2015**, 211, 680-8	7	210
129	Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles. *Journal of Medicinal Chemistry*, **2015**, 58, 5344-54	8.3	27

128	Reply to Goyal et al. *Journal of Infectious Diseases*, **2015**, 211, 1687	7	1
127	Allosteric regulation of the Plasmodium falciparum cysteine protease falcipain-2 by heme. *Archives of Biochemistry and Biophysics*, **2015**, 573, 92-9	4.1	8
126	Synthesis and in vitro antiplasmodial evaluation of 7-chloroquinoline-chalcone and 7-chloroquinoline-ferrocenylchalcone conjugates. *European Journal of Medicinal Chemistry*, **2015**, 95, 230-9	6.8	34
125	The Effect of Storage and Extraction Methods on Amplification of Plasmodium falciparum DNA from Dried Blood Spots. *American Journal of Tropical Medicine and Hygiene*, **2015**, 92, 922-5	3.2	30
124	Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E4438-47	11.5	130
123	Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 4387-96	5.9	35
122	Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network. *American Journal of Tropical Medicine and Hygiene*, **2015**, 93, 57-68	3.2	177
121	Synthesis and structure-activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the Plasmodium falciparum cysteine protease falcipain-2. *European Journal of Medicinal Chemistry*, **2015**, 90, 507-18	6.8	28
120	Estimating malaria parasite prevalence from community surveys in Uganda: a comparison of microscopy, rapid diagnostic tests and polymerase chain reaction. *Malaria Journal*, **2015**, 14, 528	3.6	43
119	Enantiopure Indolizinoindolones with in vitro Activity against Blood- and Liver-Stage Malaria Parasites. *ChemMedChem*, **2015**, 10, 2080-9	3.7	18
118	Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 3018-30	5.9	42
117	Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control. *American Journal of Tropical Medicine and Hygiene*, **2015**, 92, 903-12	3.2	116
116	Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular Assays. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 5061-4	5.9	48
115	The RTS,S/AS01 vaccine continues to show modest protection against malaria in African infants and children. *Evidence-Based Medicine*, **2015**, 20, 179		2
114	N10,N11-di-alkylamine indolo[3,2-b]quinolines as hemozoin inhibitors: design, synthesis and antiplasmodial activity. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 1530-9	3.4	9
113	Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3660-5	5.9	26
112	Probing the aurone scaffold against Plasmodium falciparum: design, synthesis and antimalarial activity. *European Journal of Medicinal Chemistry*, **2014**, 80, 523-34	6.8	45
111	1H-1,2,3-Triazole-tethered isatin-7-chloroquinoline and 3-hydroxy-indole-7-chloroquinoline conjugates: synthesis and antimalarial evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 756-9	2.9	45

110	Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. *American Journal of Tropical Medicine and Hygiene*, **2014**, 91, 54-61	3.2	53
109	Novel endoperoxide-based transmission-blocking antimalarials with liver- and blood-schizontocidal activities. *ACS Medicinal Chemistry Letters*, **2014**, 5, 108-12	4.3	36
108	Synthesis, biological evaluation, hydration site thermodynamics, and chemical reactivity analysis of β-keto substituted peptidomimetics for the inhibition of Plasmodium falciparum. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1274-9	2.9	13
107	Differential prevalence of transporter polymorphisms in symptomatic and asymptomatic falciparum malaria infections in Uganda. *Journal of Infectious Diseases*, **2014**, 210, 154-7	7	19
106	Cross-talk between malarial cysteine proteases and falstatin: the BC loop as a hot-spot target. *PLoS ONE*, **2014**, 9, e93008	3.7	7
105	Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine. *PLoS ONE*, **2014**, 9, e103200	3.7	13
104	Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. *PLoS ONE*, **2014**, 9, e105690	3.7	91
103	Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. *Clinical Infectious Diseases*, **2014**, 59, 446-53	11.6	13
102	Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. *PLoS Medicine*, **2014**, 11, e1001689	11.6	64
101	Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. *Journal of Infectious Diseases*, **2014**, 210, 344-53	7	78
100	Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. *American Journal of Tropical Medicine and Hygiene*, **2014**, 91, 833-843	3.2	167
99	Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. *Clinical Infectious Diseases*, **2014**, 58, 1404-12	11.6	67
98	β-amino-alcohol tethered 4-aminoquinoline-isatin conjugates: synthesis and antimalarial evaluation. *European Journal of Medicinal Chemistry*, **2014**, 84, 566-73	6.8	18
97	Synthesis of gallinamide A analogues as potent falcipain inhibitors and antimalarials. *Journal of Medicinal Chemistry*, **2014**, 57, 10557-63	8.3	29
96	Discovery of highly selective 7-chloroquinoline-thiohydantoins with potent antimalarial activity. *European Journal of Medicinal Chemistry*, **2014**, 84, 425-32	6.8	21
95	Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS. *Bioanalysis*, **2014**, 6, 3081-9	2.1	19
94	Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. *Clinical Infectious Diseases*, **2014**, 59, 509-16	11.6	32
93	Validation of the ligase detection reaction fluorescent microsphere assay for the detection of Plasmodium falciparum resistance mediating polymorphisms in Uganda. *Malaria Journal*, **2014**, 13, 95	3.6	20

92	Urea/oxalamide tethered β-lactam-7-chloroquinoline conjugates: synthesis and in vitro antimalarial evaluation. *European Journal of Medicinal Chemistry*, **2014**, 71, 128-34	6.8	30
91	Exploring the Molecular Basis of Qo bc1 Complex Inhibitors Activity to Find Novel Antimalarials Hits. *Molecular Informatics*, **2013**, 32, 659-70	3.8	8
90	Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds. *ACS Medicinal Chemistry Letters*, **2013**, 4, 1198-202	4.3	12
89	The interplay between drug resistance and fitness in malaria parasites. *Molecular Microbiology*, **2013**, 89, 1025-38	4.1	93
88	N-cinnamoylated chloroquine analogues as dual-stage antimalarial leads. *Journal of Medicinal Chemistry*, **2013**, 56, 556-67	8.3	46
87	Synthesis, Antiplasmodial Activity, and β-Hematin Inhibition of Hydroxypyridone-Chloroquine Hybrids. *ACS Medicinal Chemistry Letters*, **2013**, 4, 642-6	4.3	22
86	Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-phenylisoserine. *ACS Medicinal Chemistry Letters*, **2013**, 4, 637-41	4.3	27
85	Optimization of a ligase detection reaction-fluorescent microsphere assay for characterization of resistance-mediating polymorphisms in African samples of Plasmodium falciparum. *Journal of Clinical Microbiology*, **2013**, 51, 2564-70	9.7	33
84	Fitness Consequences of Polymorphisms Inferred from Culture of Ugandan Parasites. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4245-4251	5.9	17
83	PRIMACINS, N-cinnamoyl-primaquine conjugates, with improved liver-stage antimalarial activity. *MedChemComm*, **2012**, 3, 1170	5	33
82	Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. *Acta Tropica*, **2012**, 121, 184-95	3.2	133
81	Back Cover: Cinnamic Acid/Chloroquinoline Conjugates as Potent Agents against Chloroquine-Resistant Plasmodium falciparum (ChemMedChem 9/2012). *ChemMedChem*, **2012**, 7, 1692-1692	3.7	
80	1,4-naphthoquinone cations as antiplasmodial agents: hydroxy-, acyloxy-, and alkoxy-substituted analogues. *ACS Medicinal Chemistry Letters*, **2012**, 3, 1029-33	4.3	25
79	Squaric acid: a valuable scaffold for developing antimalarials?. *MedChemComm*, **2012**, 3, 489	5	28
78	Novel potent metallocenes against liver stage malaria. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1564-70	5.9	28
77	Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. *New England Journal of Medicine*, **2012**, 367, 2110-8	59.2	75
76	Falcipains and other cysteine proteases of malaria parasites. *Advances in Experimental Medicine and Biology*, **2011**, 712, 30-48	3.6	102
75	Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. *Malaria Journal*, **2011**, 10, 144	3.6	444

74	Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors. *MedChemComm*, **2011**, 2, 1201	5	19
73	Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 644-51	2.9	60
72	Design, synthesis and evaluation of 3-methylene-substituted indolinones as antimalarials. *European Journal of Medicinal Chemistry*, **2011**, 46, 927-33	6.8	26
71	Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 11405-10	11.5	236
70	Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 615-22	5.9	24
69	Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. *Journal of Infectious Diseases*, **2011**, 204, 1120-4	7	110
68	Chemical genetics of Plasmodium falciparum. *Nature*, **2010**, 465, 311-5	50.4	443
67	Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1949-54	5.9	80
66	In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1200-6	5.9	71
65	Biochemical properties of a novel cysteine protease of Plasmodium vivax, vivapain-4. *PLoS Neglected Tropical Diseases*, **2010**, 4, e849	4.8	22
64	Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. *Journal of Medicinal Chemistry*, **2010**, 53, 6129-52	8.3	93
63	Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene. *Malaria Journal*, **2010**, 9, 174	3.6	39
62	PRIMACENES: novel non-cytotoxic primaquine-ferrocene conjugates with anti-Pneumocystis carinii activity. *MedChemComm*, **2010**, 1, 199	5	24
61	Synthesis, Structure and in Vitro Biological Screening of Palladium(II) Complexes of Functionalised Salicylaldimine Thiosemicarbazones as Antimalarial and Anticancer Agents. *European Journal of Inorganic Chemistry*, **2010**, 2010, 3520-3528	2.3	74
60	Regulatory elements within the prodomain of Falcipain-2, a cysteine protease of the malaria parasite Plasmodium falciparum. *PLoS ONE*, **2009**, 4, e5694	3.7	42
59	Vinyl sulfones as antiparasitic agents and a structural basis for drug design. *Journal of Biological Chemistry*, **2009**, 284, 25697-703	5.4	190
58	Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. *BMJ, The*, **2009**, 339, b2763	5.9	66
57	Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. *Journal of Infectious Diseases*, **2009**, 200, 1650-7	7	28

56	Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity. *Journal of Medicinal Chemistry*, **2009**, 52, 852-7	8.3	124
55	Imidazoquines as antimalarial and antipneumocystis agents. *Journal of Medicinal Chemistry*, **2009**, 52, 7800-7	8.3	32
54	Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3. *PLoS ONE*, **2009**, 4, e5156	3.7	49
53	Artesunate for the treatment of severe falciparum malaria. *New England Journal of Medicine*, **2008**, 358, 1829-36	59.2	118
52	Plasmodium food vacuole plasmepsins are activated by falcipains. *Journal of Biological Chemistry*, **2008**, 283, 12870-6	5.4	92
51	Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. *Antimicrobial Agents and Chemotherapy* , **2008**, 52, 2212-22	5.9	62
50	Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. *Journal of Infectious Diseases*, **2008**, 197, 510-8	7	115
49	Complexity of Plasmodium falciparum clinical samples from Uganda during short-term culture. *Journal of Infectious Diseases*, **2008**, 198, 1554-7	7	21
48	Prophylaxis and treatment of malaria in HIV-infected populations. *Future HIV Therapy*, **2008**, 2, 453-464		2
47	A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. *PLoS ONE*, **2008**, 3, e2252	3.7	113
46	Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. *PLoS ONE*, **2008**, 3, e2390	3.7	109
45	Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. *Clinical Infectious Diseases*, **2007**, 45, 1453-61	11.6	100
44	Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3023-5	5.9	63
43	Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. *PLOS Clinical Trials*, **2007**, 2, e20		115
42	Falcipain cysteine proteases require bipartite motifs for trafficking to the Plasmodium falciparum food vacuole. *Journal of Biological Chemistry*, **2007**, 282, 24961-9	5.4	33
41	Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. *JAMA - Journal of the American Medical Association*, **2007**, 297, 2210-9	27.4	139
40	Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. *Lancet, The*, **2007**, 369, 491-8	40	102
39	Plasmodium falciparum: biochemical characterization of the cysteine protease falcipain-2R *Experimental Parasitology*, **2006**, 112, 187-92	2.1	60

38	Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. *Molecular and Biochemical Parasitology*, **2006**, 150, 96-106	1.9	131
37	Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 1893-5	5.9	129
36	Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. *PLOS Clinical Trials*, **2006**, 1, e7		89
35	Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 11503-8	11.5	87
34	Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. *Journal of Infectious Diseases*, **2006**, 193, 978-86	7	67
33	Falstatin, a cysteine protease inhibitor of Plasmodium falciparum, facilitates erythrocyte invasion. *PLoS Pathogens*, **2006**, 2, e117	7.6	68
32	Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. *American Journal of Tropical Medicine and Hygiene*, **2006**, 75, 836-42	3.2	63
31	VALIDATION OF MICROSATELLITE MARKERS FOR USE IN GENOTYPING POLYCLONAL PLASMODIUM FALCIPARUM INFECTIONS. *American Journal of Tropical Medicine and Hygiene*, **2006**, 75, 836-842	3.2	70
30	Biosynthesis, localization, and processing of falcipain cysteine proteases of Plasmodium falciparum. *Molecular and Biochemical Parasitology*, **2005**, 139, 205-12	1.9	67
29	Design, Synthesis and Evaluation of Trisubstituted Thiazoles Targeting Plasmodium Falciparum Cysteine Proteases. *Medicinal Chemistry Research*, **2005**, 14, 74-105	2.2	13
28	Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. *PLoS Medicine*, **2005**, 2, e190	11.6	78
27	The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 9138-43	11.5	107
26	Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 2983-5	5.9	114
25	Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 4384-9	11.5	234
24	Independent intramolecular mediators of folding, activity, and inhibition for the Plasmodium falciparum cysteine protease falcipain-2. *Journal of Biological Chemistry*, **2004**, 279, 3484-91	5.4	44
23	Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 8721-6	11.5	107
22	Antimalarial drug discovery: efficacy models for compound screening. *Nature Reviews Drug Discovery*, **2004**, 3, 509-20	64.1	521
21	Cysteine proteases of malaria parasites. *International Journal for Parasitology*, **2004**, 34, 1489-99	4.3	259

20	Selection of cysteine protease inhibitor-resistant malaria parasites is accompanied by amplification of falcipain genes and alteration in inhibitor transport. *Journal of Biological Chemistry*, **2004**, 279, 35236-41	5.4	30
19	Identification and biochemical characterization of vivapains, cysteine proteases of the malaria parasite Plasmodium vivax. *Biochemical Journal*, **2004**, 378, 529-38	3.8	57
18	PRINCIPAL ROLE OF DIHYDROPTEROATE SYNTHASE MUTATIONS IN MEDIATING RESISTANCE TO SULFADOXINE-PYRIMETHAMINE IN SINGLE-DRUG AND COMBINATION THERAPY OF UNCOMPLICATED MALARIA IN UGANDA. *American Journal of Tropical Medicine and Hygiene*, **2004**, 71, 758-763	3.2	31
17	Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. *American Journal of Tropical Medicine and Hygiene*, **2004**, 71, 758-63	3.2	29
16	Antimalarial drug discovery: old and new approaches. *Journal of Experimental Biology*, **2003**, 206, 3735-44	3	147
15	Stage-specific antimalarial activity of cysteine protease inhibitors. *Biological Chemistry*, **2002**, 383, 843-7	4.5	20
14	Folding of the Plasmodium falciparum cysteine protease falcipain-2 is mediated by a chaperone-like peptide and not the prodomain. *Journal of Biological Chemistry*, **2002**, 277, 14910-5	5.4	49
13	Hydrolysis of erythrocyte proteins by proteases of malaria parasites. *Current Opinion in Hematology* , **2002**, 9, 140-5	3.3	87
12	Critical role of amino acid 23 in mediating activity and specificity of vinckepain-2, a papain-family cysteine protease of rodent malaria parasites. *Biochemical Journal*, **2002**, 368, 273-81	3.8	37
11	Cysteine proteases of malaria parasites: targets for chemotherapy. *Current Pharmaceutical Design*, **2002**, 8, 1659-72	3.3	164
10	Recombinant falcipain-2 cleaves erythrocyte membrane ankyrin and protein 4.1. *Molecular and Biochemical Parasitology*, **2001**, 116, 95-9	1.9	75
9	Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. *Journal of Infectious Diseases*, **2001**, 183, 1417-20	7	131
8	Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. *Biochemical Journal*, **2001**, 360, 481-489	3.8	192
7	Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. *Journal of Biological Chemistry*, **2000**, 275, 29000-10	5.4	272
6	Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 633-8	3.4	151
5	Antimalarial synergy of cysteine and aspartic protease inhibitors. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 2254-8	5.9	114
4	Characterization of a Plasmodium vivax cysteine proteinase gene identifies uniquely conserved amino acids that may mediate the substrate specificity of malarial hemoglobinases. *Journal of Molecular Biology*, **1994**, 241, 312-6	6.5	24
3	Isolation and characterization of a cysteine proteinase gene of Plasmodium falciparum. *Molecular and Biochemical Parasitology*, **1992**, 51, 143-52	1.9	94

2	Proteases and Hemoglobin Degradation311-326		6
1	Novel 1,2,3-triazole epicinchonas: Transitioning from organocatalysis to biological activities. *Synthetic Communications*,1-21	1.7	0